Clinical Trial Update: GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study of COR388 (Cortexyme) in Alzheimer's disease completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• COR388

Snippet

Sponsor: Cortexyme Inc. | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-02-23